E

Exelixis
D

EXEL

36.200
USD
-0.34
(-0.93%)
مغلق
حجم التداول
129,341
الربح لكل سهم
2
العائد الربحي
-
P/E
23
حجم السوق
10,337,960,524
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
الأخبار
المقالات

العنوان: Exelixis

القطاع: Healthcare
الصناعة: Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.